Premium
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update
Author(s) -
Phillips Elizabeth J.,
Sukasem Chonlaphat,
WhirlCarrillo Michelle,
Müller Daniel J.,
Dunnenberger Henry M.,
Chantratita Wasun,
Goldspiel Barry,
Chen YuanTsong,
Carleton Bruce C.,
George Alfred L.,
Mushiroda Taisei,
Klein Teri,
Gammal Roseann S.,
Pirmohamed Munir
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1004
Subject(s) - oxcarbazepine , carbamazepine , pharmacogenetics , toxic epidermal necrolysis , medicine , genotype , eosinophilia , allele , pharmacology , human leukocyte antigen , guideline , dermatology , immunology , epilepsy , psychiatry , genetics , biology , pathology , antigen , gene
The variant allele HLA‐B*15:02 is strongly associated with greater risk of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA‐A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.